Cargando…

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis

Dual antiplatelet therapy (DAPT) and subsequent P2Y(12) inhibitor monotherapy, particularly ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary intervention (PCI). This meta‐analysis was designed to investigate whether short‐term DAPT followed by ticagrelor mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelbenegger, Georg, Schoergenhofer, Christian, Jilma, Bernd, Gager, Gloria M., Dizdarevic, Al Medina, Mamas, Mamas A., Parapid, Biljana, Velagapudi, Poonam, Siller‐Matula, Jolanta M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359988/ https://www.ncbi.nlm.nih.gov/pubmed/33668076 http://dx.doi.org/10.1002/cpt.2226

Ejemplares similares

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis
por: Jorda, Anselm, et al.
Publicado: (2021)

Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
por: Jorda, Anselm, et al.
Publicado: (2022)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention
por: Siller-Matula, Jolanta M., et al.
Publicado: (2014)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa, Michał J, et al.
Publicado: (2018)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Impact of extracardiac vascular disease on outcomes of 1.4 million patients undergoing percutaneous coronary intervention
por: Bashar, Hussein, et al.
Publicado: (2022)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction
por: Buchtele, Nina, et al.
Publicado: (2020)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Clopidogrel in Critically Ill Patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention
por: Koziński, Marek, et al.
Publicado: (2020)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Percutaneous Coronary Angioplasty in Patients with Cancer: Clinical Challenges and Management Strategies
por: Doolub, Gemina, et al.
Publicado: (2022)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019)

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
por: Traby, Ludwig, et al.
Publicado: (2019)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Acetylsalicylic acid in critically ill patients: a cross‐sectional and a randomized trial
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Quantitative Flow Ratio and Virtual Percutaneous Coronary Intervention for Serial Coronary Stenoses: Attractive Technology, But Still Crawling
por: Sumaya, Wael, et al.
Publicado: (2022)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Multi-phasic life-threatening anaphylaxis refractory to epinephrine managed by extracorporeal membrane oxygenation (ECMO): A case report
por: Grafeneder, Juergen, et al.
Publicado: (2022)

Complex, high‐risk percutaneous coronary intervention types, trends, and in‐hospital outcomes among different age groups: An insight from a national registry
por: Shamkhani, Warkaa, et al.
Publicado: (2022)

Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis
por: Zhang, Wen-bin, et al.
Publicado: (2021)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

Ticagrelor monotherapy after CABG—Probably not at all and definitely not forever
por: Sandner, Sigrid, et al.
Publicado: (2022)

A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study
por: Hibbert, Benjamin, et al.
Publicado: (2014)

The added value of hypertonic saline solution to furosemide monotherapy in patients with acute decompensated heart failure: A meta‐analysis and trial sequential analysis
por: Diaz‐Arocutipa, Carlos, et al.
Publicado: (2023)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7tvl0o4avbu2cvjejabhbooa9